- Home
- / Nanobiotix
Nanobiotix
Stock Price
€4.2
2024-10-29
Market Capitalization
€197.5 M
2024-10-29
Revenue
€29.6 M
FY, 2025
Nanobiotix Summary
Company Summary
- Overview
- Nanobiotix is a nanomedicine company focusing on new approaches to the treatment of cancer. Its lead technology, NBTXR3, is evaluated in locally-advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Paris, FR | view all locations
- Website
- http://www.nanobiotix.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Alain Dostie, Chief Operating Officer
Brandon Owens, Vice President, Strategic Marketing and Corporate Communication
Patrick Tricoli, Chief Executive Officer and Global Head of Business Development
Operating MetricsView all
Trademarks
300
Q2, 2020
Patents
300
Q2, 2020
Patent Families
20
Q2, 2020
LocationsView all
2 locations detected
Paris, Île-de-France HQ
France
60 rue de Wattignies
Cambridge, MA
United States
210 Broadway
Nanobiotix Financials
Summary Financials
- Revenue (FY, 2025)
- €29.6M
- Gross profit (FY, 2025)
- €32.7M
- Net income (FY, 2025)
- (€24.0M)
- Cash (FY, 2025)
- €52.8M
- EBIT (FY, 2025)
- (€10.8M)
- Enterprise value
- $240.1M